Copiktra (Duvelisib) Patent Expiration, LOE Window & CMS Spending

Copiktra (Duvelisib) by Secura Bio: FDA Orange Book core substance LOE 2032-09-24 (last listed 2035-04-26), 0 AB generics, $36.9M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSecura Bio
FDA Application & PathwayN211155 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-09-24
Last Listed Patent or Exclusivity Date2035-04-26
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$36.9M
2024 Medicare Part D Spend$31.4M
2024 Medicaid Spend$5.5M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 94.0% 2-yr change)